INmune Bio, Inc.
INMB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | -0.68 | 0.22 | -0.06 |
| FCF Yield | -35.82% | -5.92% | -19.96% | -26.44% |
| EV / EBITDA | -1.73 | 0.00 | 0.00 | 0.00 |
| Quality | ||||
| ROIC | -131.26% | -61.23% | -34.16% | -30.45% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.79 | 0.40 | 0.83 | 0.94 |
| Growth | ||||
| Revenue 3-Year CAGR | -66.55% | -5.04% | 223.96% | 565,565.28% |
| Free Cash Flow Growth | -178.47% | 47.19% | 47.85% | -386.42% |
| Safety | ||||
| Net Debt / EBITDA | 0.49 | 0.00 | 0.00 | 0.00 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 36,734.64 | 5,750.52 | 8,257.39 | 11,099.23 |